Langley Porter Psychiatric Hospital
- Type
- Teaching hospital
- Where
- San Francisco, CA
- Medicare CCN
- 054144
- Received
- $58,899,360 in 2,989 records, 2021 ($4,748,100 general, $54,151,260 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2021 | General payment | 390 | $4,748,100 |
| 2021 | Research payment | 2,599 | $54,151,260 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 2,599 | $54,151,260 |
| Grant | 89 | $2,735,726 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 91 | $781,004 |
| Space rental or facility fees (teaching hospital only) | 110 | $357,999 |
| Royalty or License | 23 | $278,491 |
| Education | 63 | $231,845 |
| Consulting Fee | 6 | $222,631 |
| Charitable Contribution | 7 | $140,385 |
| Food and Beverage | 1 | $15 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2021-12-31 | Merck Sharp & Dohme LLC | $291,992 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase II open label, single arm study to evaluate the efficacy of pembrolizumab for leukoplakia | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $254,528 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-label, Randomized, Phase 2,3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After I | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $243,372 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1, Open-label, Multi-Arm, Multi-Site Study of MK-4830 anti-ILT4 as Monotherapy and in Combination with Pembroliz | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $136,821 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Do | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $132,226 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1,Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab MK-34 | 2021 |
| 2021-12-31 | SERVIER PHARMACEUTICALS LLC | $131,352 | Research payment | Cash or cash equivalent | STUDY OF VORASIDENIB (AG-881) IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION (I | 2021 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $116,292 | Research payment | In-kind items and services | Biological, ONCOLOGY | A Phase 1, Open-label, Multi-Arm, Multi-Site Study of MK-4830 anti-ILT4 as Monotherapy and in Combination with Pembroliz | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $102,949 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671,V941 as a Monotherapy and in | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $100,918 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety andEfficacy of Pembrolizumab MK-3475 and Lenvatini | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $99,445 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recomb | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $82,360 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 2 Study Evaluating Futibatinib TAS 120 Plus Pembrolizumab in the Treatment of Advanced or Metastatic Urothelial | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $78,174 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination wit | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $63,782 | Research payment | In-kind items and services | Drug, ONCOLOGY | Phase 1 Open Label, Multicenter Study of MK-1454 Administered by Intratumoral Injection as Monotherapy and in Combinatio | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $55,262 | Research payment | In-kind items and services | Drug, ONCOLOGY | An Open-label, Randomized, Phase 2,3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After I | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $54,996 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | KEYMAKER U01 Master Study A Phase 2 Umbrella Study with Rolling Arms of Investigational Agents with either Pembrolizumab | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $51,343 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Phase Ib,II Trial of anti-PD-1 immunotherapy and Stereotactic Radiation in Patients with Recurrent Glioblastoma | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $49,532 | Research payment | In-kind items and services | Biological, ONCOLOGY | A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671,V941 as a Monotherapy and in | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $48,724 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Phase 1b,2 study of immune and targeted combination therapies in participants with RCC | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $48,724 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Phase 1b,2 study of immune and targeted combination therapies in participants with RCC | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $46,341 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Two-Arm, Open-label, Randomized Phase III Study of Pembrolizumab MK-3475 monotherapy versus standard chemotherapy in P | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $45,597 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine,Cisplatin versus Placebo Plus Gemcitabine,Cis | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $42,642 | Research payment | In-kind items and services | Biological, ONCOLOGY | A Phase 1,Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab MK-34 | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $42,337 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Clinical Trial of Pembrolizumab MK-3475 Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors KEYNOT | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $38,946 | Research payment | In-kind items and services | Drug, ONCOLOGY | A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recomb | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $29,326 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- MK-3475, SCH 900475 Based Combination Therapy f | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $29,270 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Do | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $22,746 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine,Cisplatin versus Placebo Plus Gemcitabine,Cis | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $21,191 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety andEfficacy of Pembrolizumab MK-3475 and Lenvatini | 2021 |
| 2021-12-31 | Roche Diagnostics Operations, Inc. | $17,584 | Research payment | Cash or cash equivalent | cobas c 311 Device, Core Lab | CIMRD005298 | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $12,976 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- MK-3475, SCH 900475 Based Combination Therapy f | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $9,567 | Research payment | In-kind items and services | Drug, ONCOLOGY | Phase 1 Open Label, Multicenter Study of MK-1454 Administered by Intratumoral Injection as Monotherapy and in Combinatio | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $8,359 | Research payment | In-kind items and services | Drug, ONCOLOGY | A Phase 2 Study in First Line Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma to Evaluate In | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $7,085 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase II Single-arm, Open-label Monotherapy Clinical Trial of Pembrolizumab MK-3475 in Locally Advanced,Metastatic Ren | 2021 |
| 2021-12-31 | KARL STORZ Endoscopy-America | $5,250 | Education | In-kind items and services | Device, VIDEOIMAGING | 2021 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $5,154 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized Double-Blind, Phase III Study of PlatinumPemtrexed Chemotherapy with or without Pembrolizumab MK-3475 in Fi | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $4,684 | Research payment | In-kind items and services | ZINPLAVA Biological, INFECTIOUS DISEASE | Protocol Title A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, Phar | 2021 |
| 2021-12-31 | KARL STORZ Endoscopy-America | $4,578 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $4,578 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $4,344 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $4,344 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $4,249 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $3,982 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $3,925 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab MK-3475 plus Chemotherapy vs Placebo plus Chemotherapy for | 2021 |
| 2021-12-31 | KARL STORZ Endoscopy-America | $3,638 | Education | In-kind items and services | Device, VIDEOIMAGING | 2021 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $3,480 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Phase IB Study of Pembrolizumab MK-3475 in Subjects with Select Advanced Solid Tumors | 2021 |
| 2021-12-31 | KARL STORZ Endoscopy-America | $3,016 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | Roche Diagnostics Operations, Inc. | $2,987 | Research payment | In-kind items and services | cobas c 311 Device, Core Lab | CIMRD005298 | 2021 |
| 2021-12-31 | KARL STORZ Endoscopy-America | $2,263 | Education | In-kind items and services | Device, VIDEOIMAGING | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $2,179 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $2,022 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $1,923 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $1,836 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $1,721 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III Randomized Trial of MK-3475 Versus Standard Treatment in Subjects with recurrent or metastatic head and neck | 2021 |
| 2021-12-31 | KARL STORZ Endoscopy-America | $1,374 | Education | In-kind items and services | Device, VIDEOIMAGING | 2021 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $1,365 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination wit | 2021 |
| 2021-12-31 | KARL STORZ Endoscopy-America | $1,308 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $1,229 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | AstraZeneca Pharmaceuticals LP | $988 | Research payment | In-kind items and services | Multiarm Open label multicenter phase 1b 2 study to evaluate novel combination therapies in subjects with previously tre | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $872 | Education | In-kind items and services | Device, VIDEOIMAGING | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $872 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $829 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $829 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $829 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | AstraZeneca UK Limited | $796 | Research payment | In-kind items and services | SAPHNELO Biological, Inflammation and Autoimmunity | The purpose of this study is to characterise longterm safety and tolerability of intravenous anifrolumab A Multicentre R | 2021 |
| 2021-12-31 | AstraZeneca Pharmaceuticals LP | $771 | Research payment | In-kind items and services | This is a randomized open label multi center global Phase III study to assess the efficacy and safety of durvalumab plus | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $624 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $624 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | ABBVIE INC. | $550 | Research payment | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | A Multicenter, Open-Label Phase 1b Study to Assess Safety and Efficacy of Venetoclax in Combination with Gilteritinib in | 2021 |
| 2021-12-31 | KARL STORZ Endoscopy-America | $544 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $544 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $472 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $472 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $472 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $472 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $442 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $442 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $387 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $347 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $347 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $300 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $277 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $275 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $275 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $275 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | Haemonetics Corporation | $263 | Research payment | In-kind items and services | TEG6s HEMOSTASIS SYSTEM Device, Devices | An observational trial to assess the performance of the TEG 6s diagnostic system with the Citrated K, KH, RTH, FFH Cartr | 2021 |
| 2021-12-31 | Haemonetics Corporation | $263 | Research payment | In-kind items and services | TEG6s HEMOSTASIS SYSTEM Device, Devices | An observational trial to assess the performance of the TEG 6s diagnostic system with the Citrated K, KH, RTH, FFH Cartr | 2021 |
| 2021-12-31 | Haemonetics Corporation | $263 | Research payment | In-kind items and services | TEG6s HEMOSTASIS SYSTEM Device, Devices | An observational trial to assess the performance of the TEG 6s diagnostic system with the Citrated K, KH, RTH, FFH Cartr | 2021 |
| 2021-12-31 | Haemonetics Corporation | $263 | Research payment | In-kind items and services | TEG6s HEMOSTASIS SYSTEM Device, Devices | An observational trial to assess the performance of the TEG 6s diagnostic system with the Citrated K, KH, RTH, FFH Cartr | 2021 |
| 2021-12-31 | KARL STORZ Endoscopy-America | $251 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | AstraZeneca Pharmaceuticals LP | $248 | Research payment | In-kind items and services | LYNPARZA Drug, Oncology | A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Pla | 2021 |
| 2021-12-31 | KARL STORZ Endoscopy-America | $236 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $236 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $236 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $180 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Phase 1 Open Label, Multicenter Study of MK-1454 Administered by Intratumoral Injection as Monotherapy and in Combinatio | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $180 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Phase 1 Open Label, Multicenter Study of MK-1454 Administered by Intratumoral Injection as Monotherapy and in Combinatio | 2021 |
| 2021-12-31 | KARL STORZ Endoscopy-America | $161 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $161 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $157 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $125 | Education | In-kind items and services | Device, VIDEOIMAGING | 2021 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $120 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Sche | 2021 |
| 2021-12-31 | KARL STORZ Endoscopy-America | $112 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $112 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $112 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $111 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $98 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 2 Study in First Line Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma to Evaluate In | 2021 |
| 2021-12-31 | KARL STORZ Endoscopy-America | $66 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $57 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $57 | Education | In-kind items and services | Device, VIDEOIMAGING | 2021 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $45 | Research payment | In-kind items and services | GARDASIL Biological, VACCINE | A Study to Evaluate the Efficacy of GARDASILTM in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related External Ge | 2021 |
| 2021-12-31 | AstraZeneca UK Limited | $38 | Research payment | In-kind items and services | A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib Fulvestrant Versus Placebo | 2021 | |
| 2021-12-31 | Aimmune Therapeutics, Inc. | $21 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-12-31 | KARL STORZ Endoscopy-America | $17 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $3 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | KEYMAKER U01Substudy 1 A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents with Pembrolizumab in Combi | 2021 |
| 2021-12-29 | F. Hoffmann-La Roche AG | $77,423 | Research payment | Cash or cash equivalent | ORAL DELIVERY OF MACROMOLECULES WITH DIVERSE NANOPARTICLE FORMULATION FORMATS EXPLORING THE MECHANISM OF NANOPARTICLE IN | 2021 | |
| 2021-12-29 | Merck Sharp & Dohme LLC | $18,087 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized Double-Blind, Phase III Study of PlatinumPemtrexed Chemotherapy with or without Pembrolizumab MK-3475 in Fi | 2021 |
| 2021-12-29 | United Therapeutics Corporation | $15,000 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-12-29 | JAZZ PHARMACEUTICALS INC. | $10,000 | Research payment | Cash or cash equivalent | RYLAZE Drug, HEMATOLOGY/ONCOLOGY | AN OPEN-LABEL STUDY OF JZP-458 (RC-P) IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)/LYMPHOBLASTIC LYMPHOMA (LBL) | 2021 |
| 2021-12-29 | Incyte Corporation | $10,000 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2021 | |
| 2021-12-29 | Incyte Corporation | $4,000 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2021 | |
| 2021-12-29 | Incyte Corporation | $3,000 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2021 | |
| 2021-12-29 | Gilead Sciences, Inc. | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2021 | ||
| 2021-12-29 | Gilead Sciences, Inc. | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2021 | ||
| 2021-12-29 | United Therapeutics Corporation | $2,142 | Research payment | Cash or cash equivalent | ORENITRAM Drug, PAH | EXPEDITE: A 16-WEEK MULTICENTER OPEN-LABEL STUDY OF REMODULIN INDUCTION FOLLOWED BY ORENITRAM OPTIMIZATION IN SUBJECTS W | 2021 |
| 2021-12-29 | JAZZ PHARMACEUTICALS INC. | $2,000 | Research payment | Cash or cash equivalent | RYLAZE Drug, HEMATOLOGY/ONCOLOGY | AN OPEN-LABEL STUDY OF JZP-458 (RC-P) IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)/LYMPHOBLASTIC LYMPHOMA (LBL) | 2021 |
| 2021-12-29 | Incyte Corporation | $840 | Research payment | In-kind items and services | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2021 | |
| 2021-12-28 | Medicines360 | $17,423 | Research payment | Cash or cash equivalent | Liletta Device, Obstetrics/Gynecology (Women's Health) | A Phase 3 multicenter, open-label study of a Levonorgestrel 52 mg Intrauterine System for the treatment of heavy Menstru | 2021 |
| 2021-12-28 | Takeda Pharmaceuticals U.S.A., Inc. | $974 | Research payment | Cash or cash equivalent | GATTEX Drug, INTERNAL MEDICINE | A PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME | 2021 |
| 2021-12-28 | Incyte Corporation | $840 | Research payment | In-kind items and services | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2021 | |
| 2021-12-28 | Takeda Pharmaceuticals U.S.A., Inc. | $779 | Research payment | Cash or cash equivalent | GATTEX Drug, INTERNAL MEDICINE | A PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME | 2021 |
| 2021-12-28 | Deciphera Pharmaceuticals Inc. | $500 | Research payment | Cash or cash equivalent | A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | 2021 | |
| 2021-12-27 | Regeneron Pharmaceuticals, Inc. | $5,334 | Research payment | Cash or cash equivalent | EYLEA Biological, OPHTHALMOLOGY | RANDOMIZED, CONTROLLED, MULTI-CENTER STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF INTRAVITREAL AFLIBERCEPT | 2021 |
| 2021-12-27 | Incyte Corporation | $840 | Research payment | In-kind items and services | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2021 | |
| 2021-12-27 | PFIZER INC. | $450 | Research payment | Cash or cash equivalent | UCSFPFIZER CTI | 2021 | |
| 2021-12-24 | Genentech, Inc. | $49,100 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PHASE 3 STUDY OF ANTI PDL1 WITH ABRAXANE IN TN MBC | 2021 |
| 2021-12-24 | Genentech, Inc. | $24,152 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PHASE 3 STUDY OF ANTI PDL1 WITH ABRAXANE IN TN MBC | 2021 |
| 2021-12-24 | Genentech, Inc. | $21,109 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | PH 3 STUDY OF GLOFITAMAB WITH GEMOX VS RITUXIMAB WITH GEMOX IN PATIENTS WITH R R DLBCL | 2021 |
| 2021-12-24 | PFIZER INC. | $14,151 | Research payment | Cash or cash equivalent | PHASE 3 OPENLABEL SINGLEARM STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF07055480 RECOMBINANT AAV26 HUMAN FACTOR VIII | 2021 | |
| 2021-12-24 | Genentech, Inc. | $9,766 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PHASE 3 STUDY OF ANTI PDL1 WITH ABRAXANE IN TN MBC | 2021 |
| 2021-12-24 | Janssen Research & Development, LLC | $4,234 | Research payment | Cash or cash equivalent | DARZALEX Biological, Oncology | Phase II Study of Daratumumab in Combination with Azacitidine and Dexamethasone in Relapsed Refractory Multiple Myeloma | 2021 |
| 2021-12-23 | Genentech, Inc. | $204,378 | Research payment | Cash or cash equivalent | GN41791 SPINAL CORD IN GN41791 OCREVUS TRAIL | 2021 | |
| 2021-12-23 | Epizyme, Inc. | $2,835 | Research payment | Cash or cash equivalent | TAZVERIK Drug, ONCOLOGY | A PHASE 2, MULTICENTER STUDY OF THE EZH2 INHIBITOR TAZEMETOSTAT IN ADULT SUBJECTS WITH INI1-NEGATIVE TUMORS OR RELAPSED/ | 2021 |
| 2021-12-23 | SERVIER PHARMACEUTICALS LLC | $1,725 | Research payment | Cash or cash equivalent | STUDY OF VORASIDENIB (AG-881) IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION (I | 2021 | |
| 2021-12-23 | PFIZER INC. | $1,596 | Research payment | Cash or cash equivalent | A PHASE 2 12 WEEK ADAPTIVE OPEN LABEL SEQUENTIAL COHORT TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND PHARMACOK | 2021 | |
| 2021-12-23 | TAIHO ONCOLOGY, INC. | $158 | Research payment | Cash or cash equivalent | AN OPEN-LABEL EXPANDED ACCESS PROGRAM OF FUTIBATINIB (TAS-120) IN PATIENTS WITH ADVANCED CHOLANGIOCARCINOMA HARBORING FG | 2021 | |
| 2021-12-23 | Bausch Health US, LLC | $15 | Food and Beverage | In-kind items and services | APLENZIN Drug, Neurology | 2021 | |
| 2021-12-22 | Merck Sharp & Dohme LLC | $248,471 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase II, Open-Label, Multi-Center Trial of PDS0101 ImmunoMAPK-RDOTAP,HPV-16 E6 & E7 peptides and Pembrolizumab in Pat | 2021 |
| 2021-12-22 | Cerus Corporation | $115,000 | Research payment | Cash or cash equivalent | INTERCEPT BLOOD SYSTEM FOR PLATELETS Device, DEVICE-TRANSFUSION | 2021 | |
| 2021-12-22 | Merck Sharp & Dohme LLC | $49,779 | Research payment | Cash or cash equivalent | Drug, ONCOLOGY | A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recomb | 2021 |
| 2021-12-22 | Zogenix Inc. | $22,408 | Research payment | Cash or cash equivalent | Fintepla Drug, Treatment of seizures | LGS Efficacy & Safety | 2021 |
| 2021-12-22 | Genentech, Inc. | $16,299 | Research payment | Cash or cash equivalent | Drug | A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS | 2021 |
| 2021-12-22 | Gilead Sciences, Inc. | $14,956 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilof | 2021 | |
| 2021-12-22 | PFIZER INC. | $13,773 | Research payment | Cash or cash equivalent | A TWOPART PHASE 1AB OPENLABEL MULTICENTER TRIAL EVALUATING PHARMACOKINETICS SAFETY AND EFFICACY OF PF 07284890 ARRY 461 | 2021 | |
| 2021-12-22 | Genentech, Inc. | $10,427 | Research payment | Cash or cash equivalent | Drug | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | 2021 |
| 2021-12-22 | Intercept Pharmaceuticals, Inc. | $4,403 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2021 |
| 2021-12-22 | Regeneron Pharmaceuticals, Inc. | $4,312 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN PEDIATRIC PA | 2021 |
| 2021-12-22 | GE HEALTHCARE | $3,724 | Research payment | Cash or cash equivalent | A Phase 3 Open label Multicenter Study of Flurpiridaz (18F) Injection for Positive Emission Tomography (PET) Imaging for | 2021 | |
| 2021-12-22 | GE HEALTHCARE | $3,591 | Research payment | Cash or cash equivalent | A Phase 3 Open label Multicenter Study of Flurpiridaz (18F) Injection for Positive Emission Tomography (PET) Imaging for | 2021 | |
| 2021-12-22 | Intercept Pharmaceuticals, Inc. | $3,188 | Research payment | Cash or cash equivalent | Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic | 2021 | |
| 2021-12-22 | Olympus America Inc. | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | MULTIDEBRIDER HANDPIECE, ANGLED DIEGO ELITE Device, Ear, Nose, Throat | 2021 | |
| 2021-12-22 | Intercept Pharmaceuticals, Inc. | $2,144 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2021 |
| 2021-12-22 | Incyte Corporation | $525 | Research payment | In-kind items and services | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2021 | |
| 2021-12-22 | Biohaven Pharmaceuticals, Inc. | $318 | Research payment | In-kind items and services | A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Evaluate the Efficacy and Safety of BHV-3241 in | 2021 | |
| 2021-12-21 | Medical Device Business Services, Inc. | $40,000 | Grant | Cash or cash equivalent | LCP Device, Trauma | 2021 | |
| 2021-12-21 | Genentech, Inc. | $37,044 | Research payment | Cash or cash equivalent | GN41791 SPINAL CORD IN GN41791 OCREVUS TRAIL | 2021 | |
| 2021-12-21 | E.R. Squibb & Sons, L.L.C. | $26,692 | Research payment | Cash or cash equivalent | Adaptive Pan Malignancy Study for indications in which there is no approved immunomodulating therapy or BMS registration | 2021 | |
| 2021-12-21 | Haemonetics Corporation | $12,967 | Research payment | In-kind items and services | TEG6s HEMOSTASIS SYSTEM Device, Devices | An observational trial to assess the performance of the TEG 6s diagnostic system with the Citrated K, KH, RTH, FFH Cartr | 2021 |
| 2021-12-21 | Cook Research Incorporated | $5,087 | Research payment | Cash or cash equivalent | Dr. Chuter's P-IDE for Zenith t-Branch | 2021 | |
| 2021-12-21 | Haemonetics Corporation | $3,990 | Research payment | In-kind items and services | TEG6s HEMOSTASIS SYSTEM Device, Devices | An observational trial to assess the performance of the TEG 6s diagnostic system with the Citrated K, KH, RTH, FFH Cartr | 2021 |
| 2021-12-21 | Haemonetics Corporation | $3,990 | Research payment | In-kind items and services | TEG6s HEMOSTASIS SYSTEM Device, Devices | An observational trial to assess the performance of the TEG 6s diagnostic system with the Citrated K, KH, RTH, FFH Cartr | 2021 |
| 2021-12-21 | Medical Device Business Services, Inc. | $2,470 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-12-21 | Incyte Corporation | $525 | Research payment | In-kind items and services | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2021 | |
| 2021-12-21 | ABBVIE INC. | $118 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy an | 2021 |
| 2021-12-21 | Abbott Laboratories | $4 | Research payment | In-kind items and services | i-STAT 1 wireless analyser Device, Point of Care | Assay Cartridge Development for Traumatic Brain Injury (TBI) Diagnostic Device | 2021 |
| 2021-12-21 | Abbott Laboratories | $4 | Research payment | In-kind items and services | i-STAT 1 wireless analyser Device, Point of Care | Assay Cartridge Development for Traumatic Brain Injury (TBI) Diagnostic Device | 2021 |
| 2021-12-21 | Abbott Laboratories | $4 | Research payment | In-kind items and services | i-STAT 1 wireless analyser Device, Point of Care | Assay Cartridge Development for Traumatic Brain Injury (TBI) Diagnostic Device | 2021 |
| 2021-12-20 | Novartis Pharmaceuticals Corporation | $39,268 | Research payment | Cash or cash equivalent | PIQRAY Drug, ONCOLOGY | A PHASE IB STUDY OF CISPLATIN PLUS BYL719 IN HPV ASSOCIATED TUMORS | 2021 |
| 2021-12-20 | BioMarin Pharmaceutical Inc. | $33,932 | Research payment | Cash or cash equivalent | A Phase 2 Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children with Achondrop | 2021 | |
| 2021-12-20 | Eisai Inc. | $18,220 | Research payment | Cash or cash equivalent | A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety | 2021 | |
| 2021-12-20 | Janssen Research & Development, LLC | $17,512 | Research payment | Cash or cash equivalent | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly D | 2021 | |
| 2021-12-20 | Janssen Research & Development, LLC | $17,038 | Research payment | Cash or cash equivalent | Phase 2 Randomized Double blind Placebo controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed C | 2021 | |
| 2021-12-20 | Eli Lilly and Company | $15,800 | Research payment | Cash or cash equivalent | PREVENTIVE TREATMENT OF MIGRAINE: OUTCOMES FOR PATIENTS IN REAL-WORLD HEALTHCARE SYSTEMS (TRIUMPH) | 2021 | |
| 2021-12-20 | Genentech, Inc. | $15,020 | Research payment | Cash or cash equivalent | ROZLYTREK Biological, BioOncology | STARTRK 2 RXDX 101 02 | 2021 |
| 2021-12-20 | BioMarin Pharmaceutical Inc. | $11,230 | Research payment | Cash or cash equivalent | A Phase 2 Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children with Achondrop | 2021 | |
| 2021-12-20 | BioMarin Pharmaceutical Inc. | $9,040 | Research payment | Cash or cash equivalent | A Phase 2 Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children with Achondrop | 2021 | |
| 2021-12-20 | Gilead Sciences, Inc. | $4,865 | Research payment | Cash or cash equivalent | A Proof-of-Concept, Open-Label Study Evaluating the Safety and Tolerability of Cilofexor in Subjects with Primary Sclero | 2021 | |
| 2021-12-20 | Janssen Research & Development, LLC | $2,620 | Research payment | Cash or cash equivalent | A Phase 1 First in Human Dose Escalation Study of JNJ63898081 in Subjects with Advanced Stage Solid Tumors | 2021 | |
| 2021-12-20 | Medical Device Business Services, Inc. | $2,500 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-12-20 | Janssen Research & Development, LLC | $1,933 | Research payment | Cash or cash equivalent | A Phase 1b2 Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against BCMA in Sub | 2021 | |
| 2021-12-20 | Janssen Research & Development, LLC | $1,020 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo | 2021 | |
| 2021-12-20 | Incyte Corporation | $525 | Research payment | In-kind items and services | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2021 | |
| 2021-12-20 | GENZYME CORPORATION | $266 | Research payment | Cash or cash equivalent | Fabry LSD Data Registry | 2021 | |
| 2021-12-20 | GENZYME CORPORATION | $133 | Research payment | Cash or cash equivalent | Gaucher LSD Data Registry | 2021 | |
| 2021-12-20 | Abbott Laboratories | $4 | Research payment | In-kind items and services | i-STAT 1 wireless analyser Device, Point of Care | Assay Cartridge Development for Traumatic Brain Injury (TBI) Diagnostic Device | 2021 |
| 2021-12-20 | Abbott Laboratories | $4 | Research payment | In-kind items and services | i-STAT 1 wireless analyser Device, Point of Care | Assay Cartridge Development for Traumatic Brain Injury (TBI) Diagnostic Device | 2021 |
| 2021-12-20 | Abbott Laboratories | $4 | Research payment | In-kind items and services | i-STAT 1 wireless analyser Device, Point of Care | Assay Cartridge Development for Traumatic Brain Injury (TBI) Diagnostic Device | 2021 |
| 2021-12-20 | Abbott Laboratories | $4 | Research payment | In-kind items and services | i-STAT 1 wireless analyser Device, Point of Care | Assay Cartridge Development for Traumatic Brain Injury (TBI) Diagnostic Device | 2021 |
| 2021-12-20 | Abbott Laboratories | $4 | Research payment | In-kind items and services | i-STAT 1 wireless analyser Device, Point of Care | Assay Cartridge Development for Traumatic Brain Injury (TBI) Diagnostic Device | 2021 |
| 2021-12-20 | Abbott Laboratories | $0 | Research payment | In-kind items and services | i-STAT 1 wireless analyser Device, Point of Care | Assay Cartridge Development for Traumatic Brain Injury (TBI) Diagnostic Device | 2021 |
| 2021-12-20 | Abbott Laboratories | $0 | Research payment | In-kind items and services | i-STAT 1 wireless analyser Device, Point of Care | Assay Cartridge Development for Traumatic Brain Injury (TBI) Diagnostic Device | 2021 |
| 2021-12-17 | Merck Sharp & Dohme LLC | $329,632 | Research payment | Cash or cash equivalent | Biological, ONCOLOGY | A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671,V941 as a Monotherapy and in | 2021 |
The latest 200 records of 2,989.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In San Francisco, CA, county San Francisco County, CA, state California; placed by its city name.
| Measure | Place (city or town) San Francisco, CA | County San Francisco County, CA | State California |
|---|---|---|---|
| Population B01003 | 830,235 | 830,235 | 39,287,377 |
| Population, 2020 census P1 | 873,965 | 873,965 | 39,538,223 |
| Median age B01002 | 40.0 | 40.0 | 37.9 |
| Under 18 B01001 | 13.7% | 13.7% | 22.0% |
| 65 and over B01001 | 17.6% | 17.6% | 15.7% |
| Households B11001 | 363,970 | 363,970 | 13,548,091 |
| Foreign born B05002 | 34.0% | 34.0% | 27.0% |
| Median household income B19013 | $140,970 | $140,970 | $99,122 |
| Median family income B19113 | $171,141 | $171,141 | $113,346 |
| Per capita income B19301 | $92,289 | $92,289 | $49,513 |
| Poverty rate B17001 | 11.2% | 11.2% | 12.0% |
| Unemployment rate B23025 | 6.1% | 6.1% | 6.6% |
| Civilian labor force B23025 | 507,262 | 507,262 | 20,068,466 |
| Mean commute (minutes) B08013 | 30.4 | 30.4 | 28.7 |
| Bachelor's degree or higher B15003 | 60.3% | 60.3% | 37.1% |
| Housing units B25001 | 414,602 | 414,602 | 14,644,735 |
| Owner-occupied B25003 | 38.2% | 38.2% | 55.9% |
| Renters B25003 | 61.8% | 61.8% | 44.1% |
| Median home value B25077 | $1,394,500 | $1,394,500 | $734,700 |
| Median gross rent B25064 | $2,476 | $2,476 | $2,036 |
| White, not Hispanic B03002 | 36.8% | 36.8% | 33.8% |
| Black B03002 | 4.7% | 4.7% | 5.2% |
| Hispanic or Latino B03002 | 16.2% | 16.2% | 40.2% |
| Asian B03002 | 34.9% | 34.9% | 15.3% |
| American Indian and Alaska Native B03002 | 0.2% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in San Francisco, CA.
Comments